Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 73,746	$ 54,024	$ 75,440	$ 54,486
Operating costs and expenses:
Cost of license revenue and products sold	700	109	2,048	109
Research and development	108,400	101,960	216,049	224,519
Selling, general and administrative	36,426	45,970	80,139	91,377
Restructuring, impairment and related charges	8,396		31,058
Total operating costs and expenses	153,922	148,039	329,294	316,005
Loss from operations	(80,176)	(94,015)	(253,854)	(261,519)
Other income (expense), net:
Interest income	766	323	1,033	717
Interest expense	(20,279)	(10,839)	(40,623)	(20,577)
Gain from sale of priority review voucher, net	107,946		107,946
Other income (expense), net	(10,816)	2,457	(18,391)	8,223
Total other income (expense), net	77,617	(8,059)	49,965	(11,637)
Net income (loss)	(2,559)	(102,074)	(203,889)	(273,156)
Net loss (income) attributable to redeemable convertible noncontrolling interests and noncontrolling interests	(7,297)	5,726	(2,364)	13,729
Net loss attributable to common stockholders of BridgeBio	$ (9,856)	$ (96,348)	$ (206,253)	$ (259,427)
Net loss per share attributable to common stockholders of BridgeBio, basic	$ (0.07)	$ (0.66)	$ (1.41)	$ (1.82)
Net loss per share attributable to common stockholders of BridgeBio, diluted	$ (0.07)	$ (0.66)	$ (1.41)	$ (1.82)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic	146,684,804	146,754,299	146,285,694	142,713,463
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted	146,684,804	146,754,299	146,285,694	142,713,463
License and Services Revenue
Revenue:
Total revenue	$ 73,746	$ 53,037	$ 73,981	$ 53,499
Product Sales
Revenue:
Total revenue		$ 987	$ 1,459	$ 987